Biodegradable Implant Including Naltrexone
AssigneeBiocorrx
InventorsBrady J. Granier, Ashok Kumar, Vitalii E. Stelmakh, Robert P. Giannini, JR., Andrew Peter Mallon, George Edward Sherman, JR.
Life of this patent
Estimating the term…
Abstract
A formulation of naltrexone that ameliorates undesirable localized reactions at the site of implantation.
Claims101
A pharmaceutically-acceptable formulation consisting of an opioid antagonist and magnesium stearate or pharmaceutically-acceptable salts thereof,
- wherein said opioid antagonist is (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a, 13-hexahydro-1H-4, 12-methanobenzofuro[3,2-e]isoquinolin-7-one or salts thereof or anhydrous base or prodrugs thereof;
- wherein the amount of magnesium stearate in the formulation is less than 1% by weight;
- and
- wherein the magnesium stearate does not cause tissue irritation.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.